$3.80
2.98%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US0021201035
Symbol
ATYR

aTyr Pharma, Inc. Stock price

$3.82
-3.11 44.89% 1M
-17.40 82.00% 6M
-27.50 87.80% YTD
-22.24 85.34% 1Y
-43.38 91.91% 3Y
-316.18 98.81% 5Y
-1,984.18 99.81% 10Y
-8,368.18 99.95% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
+0.13 3.52%
ISIN
US0021201035
Symbol
ATYR
Industry

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$9.1m
Enterprise Value
$-47.8m
Net debt
positive
Cash
$57.4m
Shares outstanding
2.5m
Valuation
P/E
-
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.9 | 0.8
P/B
0.2
Financial Health
Equity Ratio
72.6%
Return on Equity
-109.8%
ROCE
-
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$5.0m | -
SBC as % of FCF
-
SBC Growth 1Y
24.3%
Share Count Growth 1Y
-97.4%
Shareholder Yield
97.4%
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
$-54.8m | $-59.8m
Growth
Revenue | estimate
- | -100.0%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
1.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
$-22.4
Short interest
11.8%
Employees
59
Rev per Employee
$0.0

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a aTyr Pharma, Inc. forecast:

9x Buy
60%
6x Hold
40%

Analyst Opinions

15 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
60%
Hold
40%

aTyr Pharma, Inc. Events

Past Events
MAY
11
Special Call - aTyr Pharma, Inc.
6 months ago

Financial data from aTyr Pharma, Inc.

Dec '25
+/-
%
0.19 0.19
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
28% 28%
9,263%
- Research and Development Expense 60 60
11% 11%
31,695%
-77 -77
15% 15%
-40,505%
- Depreciation and Amortization 0.66 0.66
7% 7%
347%
EBIT (Operating Income) EBIT -78 -78
14% 14%
-40,856%
Net Profit -74 -74
16% 16%
-39,011%

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
GlobeNewsWire
●
one day ago
ATYR2810 substantially inhibits tumor growth and metastasis of osteosarcoma to the lungs, the main driver of poor outcomes, in preclinical studies.  Anti-tumor benefits continued after treatment with ATYR2810 ended, without evidence of overt toxicity, supporting the potential of ATYR2810 in an aggressive cancer.
Neutral
GlobeNewsWire
●
23 days ago
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of results from the Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients ...
Neutral
GlobeNewsWire
●
25 days ago
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-40, effective a...
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Shukla
Employees 59
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today